Flotetuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Flotetuzumab
DrugBank Accession Number
DB15223
Background

Flotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS).

Type
Biotech
Groups
Investigational
Synonyms
  • Flotetuzumab

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
0AHT0IC02G
CAS number
1664355-28-5

References

General References
Not Available
Wikipedia
Flotetuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentRelapsed Acute Myelogenous Leukemia (AML)1
2WithdrawnTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemia Recurrent / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hairy Cell Leukemia (HCL) / Interleukin-3 Receptor Subunit Alpha Positive / Leukemia, Acute / Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Hematologic Malignancy / Recurrent Hodgkin Lymphoma / Refractory Acute Lymphoblastic Leukemia / Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm / Refractory Hematologic Malignancy / Refractory Hodgkin Lymphoma / Systemic Mastocytosis1
1RecruitingTreatmentAcute, recurrent Myeloid Leukemia / Refractory Acute Myelogenous Leukemia (AML)1
1RecruitingTreatmentRecurrent Acute Leukemia / Recurrent B Acute Lymphoblastic Leukemia / Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Hairy Cell Leukemia / Recurrent Hematologic Malignancy / Recurrent Hodgkin Lymphoma / Recurrent T Acute Lymphoblastic Leukemia / Refractory Acute Leukemia / Refractory B Acute Lymphoblastic Leukemia / Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Hairy Cell Leukemia / Refractory Hematologic Malignancy / Refractory Hodgkin Lymphoma / Refractory T Acute Lymphoblastic Leukemia / Systemic Mastocytosis1
1, 2RecruitingTreatmentAcute Myeloid Leukemia (AML)1
Not AvailableAvailableNot AvailableAcute Myeloid Leukemia (AML) / AML, Adult Recurrent1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 15:01 / Updated on February 21, 2021 18:55